Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
LUTATHERA AND PLUVICTO is a federal award for W40m Mrc0 West held by Novartis Pharmaceuticals Corp. Estimated value $3.2M ($3.2M obligated). Current period of performance ends Sep 30, 2026. Place of performance: SAN ANTONIO TX.
Recompete timing
PublicCurrent PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordNovartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W81K0025FA195?
W81K0025FA195 (Lutathera and pluvicto) is a W40m Mrc0 West award with a potential value of $3.2M, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded W81K0025FA195?
W40m Mrc0 West awarded W81K0025FA195 to Novartis Pharmaceuticals Corp (potential $3.2M).
Who is the incumbent on W81K0025FA195?
Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Novartis Pharmaceuticals Corp’s W81K0025FA195 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.